« Back
Home /
KCL-286

KCL-286

Item no.	HY-111573-25mg
Manufacturer	MedChem Express
CASRN	1952276-71-9
Amount	25 mg
Quantity options	1 ea 10 mg 25 mg 50 mg 5 mg
Specific against	other
Citations	[1]Goncalves MB, et al. Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-β agonist for treatment of spinal cord injury, in male healthy participants. Br J Clin Pharmacol. 2023 Jul 15..
Smiles	CC1=CC=C(C)C2=C1OC(C3=NC(C4=CC=C(C(O)=O)C=C4)=NO3)=C2
Available
Product Description	Anticancer agent 168 is an orally active retinoic acid receptor (RAR/RXR) beta2 agonist with ameliorating effects on spinal cord injury (SCI)[1].
Shipping	Room temperature
Manufacturers Applications	Metabolism-sugar/lipid metabolism
MolecularWeight	334.33
Clinical Information	No Development Reported
Manufacturers Research Area	Others
Solubility	10 mM in DMSO
Target	RAR/RXR
Manufacturers Target	RAR/RXR
Manufacturers Pathway	Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 25 mg

available

Request delivery time